Major Initiatives
NCI Experimental Therapeutics Program (NExT)
Advances in molecular medicine have created new challenges for the design and conduct of cancer clinical trials. Through a new, joint early therapeutics development program, extramural and intramural teams have prioritized a pipeline of NCI-driven targeted therapeutics for development. More…
RFI-Chemical Biology Consortium
The NCI, through its Operations and Technical Support Prime Contractor SAIC-Frederick, Inc., is seeking input and ideas from the scientific community and the biotechnology and pharmaceutical sector about an innovative initiative that will bridge the gap between basic scientific findings and NCI-supported clinical research and in the process establish the NCI as a leader in he area of innovative cancer therapeutics discovery. More…
Program for the Assessment of Clinical Cancer Trials
The Program for the Assessment of Clinical Cancer Tests (PACCT) focuses on developing tests for cancer diagnosis, prognosis, and prediction of response to therapy. Significant research and development are involved in producing a test that is reliable enough for routine clinical use. More…
Restructuring NCI Clinical Trials
DCTD is playing a leading role in the implementation of 22 strategic initiatives to restructure the conduct of NCI-supported clinical trials, as recommended by the National Cancer Advisory Board’s Clinical Trials Working Group (CTWG). More…
Industry-Academic Partnerships for Development of Biomedical Imaging Systems and Methods that Are Cancer-Specific
This initiative fosters partnerships between academic researchers and industry by providing “seed” grants for collaborative in vivo imaging research and for projects to help validate new approaches to improve early detection, screening, diagnosis, image-guided interventions, and assessment of response to therapy. More…
In Vivo Cellular and Molecular Imaging Centers
In Vivo Cellular and Molecular Imaging Center (ICMIC) grants bring together interdisciplinary scientific teams to lead cutting-edge cancer molecular imaging research in P50 center grants that last five years. More…
Clinical Trials Cooperative Group Program
DCTD supports 12 organizations conducting large, multicenter, randomized phase III cancer treatment trials through the Clinical Trials Cooperative Group Program. More…
Pediatric Clinical Trials Cooperative Groups and Consortia
DCTD has a clinical trials program devoted exclusively to children and adolescents with cancer. More…
Office of Cancer Complementary and Alternative Medicine (OCCAM)
The Office of Cancer Complementary and Alternative Medicine (OCCAM), recently relocated to DCTD, aims to increase the amount of high-quality cancer research and information about the use of complementary and alternative modalities.
Rapid Access to Intervention Development—for Academics
NCI supports drug development through a variety of initiatives, including the Rapid Access to Intervention Development (RAID) program. More…
Charting the Course for Preoperative Breast Cancer Therapy
Preoperative systemic chemotherapy has become firmly established as part of the standard of care for locally advanced invasive breast cancer and inflammatory breast cancer. There is also considerable interest in the community in using preoperative therapy — also known as neoadjuvant therapy — in a wider population of women with earlier stages of breast cancer. More…
